The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C10-C30alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting o
The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C10-C30alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin.
대표청구항▼
The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C10-C30alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting o
The invention relates to a wet wipe product comprising a substrate and an emulsion. The emulsion comprising: an acrylate/C10-C30alkyl acrylate cross polymer emulsifier; salicylic acid; a nonionic surfactant; and a lipophillic component. The nonionic surfactant is selected from the group consisting of (i) a polymeric ether, (ii) a mixture of laurate esters of sorbitol and sorbital anhydrides condensed with ethylene oxide; and (iii) mixtures thereof. The invention also relates to a method for depositing salicylic acid to mammalian skin comprising topically applying the wipe product described above to the skin to be treated. The emulsion according to the invention produces an aesthetically pleasing product, capable of removing non-water proof make-up and able to deliver salicylic acid to the skin and is mild on the skin. Infections "Evidence of unique metabolic effects of protease inhibitors", Chicago, IL, p. 414 (Feb. 1-5, 1998). Keruly et al., 5thConference on Retroviruses and Opportunistic Infections "Diabetes and hyperglycemia in patients receiving protease inhibitors", Chicago, IL, p. 415 (Feb. 1-5, 1998). Dong et al., 5thConference on Retroviruses and Opportunistic Infections "Diabetes and use of protease inhibitors", Chicago, IL, p. 416 (Feb. 1-5, 1998). Lo et al., "Buffalo hump" In men with HIV-1 infection, The Lancet, 351:867-870 (Mar. 21, 1998). Miller et al., "Visceral abdominal-fat accumulation associated with use of indinavir", The Lancet, 351:871-875 (Mar. 21, 1998). Viraben et al., "Indinavir-associated lipodystrophy", AIDS, 12:F37-F39 (1998). Adelman et al., "In vitro deletional mutagenesis for bacterial production of the 20,000-Dalton form of human pituitary growth hormone", DNA, 2:183-193 (1983). Albertsson-Wikland et al., "Daily subcutaneous administration of human growth hormone in growth hormone deficient children", Acta Poediatr Scand, 75:89-97 (1986). Becker et al., "Chemical physical, and biological characterization of a dimeric form of biosynthetic human growth hormone", Biotechnology and Applied Biochemistry, 9:478-487 (1987). Bewley et al., "The chemistry of human pituitary growth hormone", Adv. Emzymol, Related Areas, 42:73-166 (1975). Denoto et al., "Human growth hormone DNA sequence and mRNA structure: possible alternative splicing", Nucleic Acids Research, 9:3718-3731 (1981). Hendricks et al., "Plasma clearance of intravenously administered pituitary human growth hormone: gel filtration studies of heterogeneous components", Journal of Clinical endocrinology and Metabolism, 60:864-867 (1985). J.o slashed.rgensen et al., "Serum profiles and short-term metabolic effect of pituitary and authentic biosynthetic human growth hormone in man a double-blind cross-over study", Acta Endocrinologica (Copenh), 116:381-386 (1987). J.o slashed.rgensen et al., "Pharmacokinetics of biosynthetic and pituitary human growth hormones in rats", Pharmacology & Toxicology, 63:129-134 (1988). Lewis et al., "An interchain disulfide dimmer of human growth hormone*", The Journal of Biological Chemistry, 252:3697-3702 (1977). Lewis et al., "Enhancement of the hyperglycemic activity of human growth hormone by enzymic modification", Endo. 101:1587-1603 (1977). Lewis et al., "Human Growth hormone; additional members of the complex*", Endo, 104:1256-1265 (1979). Lewis et al., "Altered proteolytic cleavage of human growth hormone as a result of deamidation", The Journal Of Biological Chemistry, 256:11645-11650 (1981). Ho et al., "Indinavir-associated facial lipodystrophy in HIV-infected patients", AIDS Patient Care and STDs, 13:11-16 (1999). Kosmiski et al., "An increase in abdominal girth on protease inhibitor therapy is associated with visceral obesity and metabolic disturbances that closely resemble syndrome", 1stInternational Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 49-55 (1999). Henry et al., "Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities", The Lancet, 352:1031-1035 (1998). Engelson et al., "Altered body fat distribution in HIV infection:regional body composition measurements by whole body MRI and DXA scans", 12thWorld AIDS Conference Geneva, 471-471 (Jun. 28-Jul. 3, 1998). Henry et al., "Severe premature coronary artery disease with protease inhibitors", The Lancet, 351:1328 (1998). Carr et al., "Pathogenesis of HIV-1-proteases inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance", The Lancet, 351:1881-1883 (1998). Carr et al., "A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors", AIDS, F51-F58 (1998). Brinkman et al., "The first international workshop on adverse drug reactions and lipodystrophy in HIV session 4:
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (3)
Ha Robert B. K. (Milford OH) Fowler Timothy J. (Cincinnati OH) Deckner George E. (Cincinnati OH), Cleansing emulsions.
Blieszner Kathleen Clare (Cincinnati OH) Deckner George Endell (Cincinnati OH), Personal care compositions and wipe products containing the compositions.
Mundschau, Stacy Averic; Kieffer, Philip Eugene; Cunningham, Corey Thomas; Kasper, Robert E, Dispersible moist wipe with emulsion for prevention of skin irritation.
Cunningham, Corey Thomas; Seidling, Jeffery Richard; Kroll, Lisa Marie; Mundschau, Stacy Averic, Stable emulsion for prevention of skin irritation and articles using same.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.